01/07/2026
Based on feedback from the FDA, Aspire Biopharma plans on completing a multicenter clinical trial and then seeking regulatory approval for its new high-dose sublingual aspirin therapy.
Cardiovascular Business is a news, business and technology source for cardiovascular medicine.
Providence, RI
| Monday | 8:30am - 5pm |
| Tuesday | 8:30am - 5pm |
| Wednesday | 8:30am - 5pm |
| Thursday | 8:30am - 5pm |
| Friday | 8:30am - 5pm |
Be the first to know and let us send you an email when Cardiovascular Business posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Send a message to Cardiovascular Business: